New antibody drug aims to ease endometriosis pain in major trial
NCT ID NCT07318688
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests HMI-115, a monoclonal antibody, in 540 women with moderate to severe endometriosis pain. Participants receive either the drug or a placebo for 24 weeks, with a 28-week extension. The goal is to see if HMI-115 reduces menstrual and pelvic pain better than placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HMI-115 (a human monoclonal antibody)
What this could lead to
If it works, this could offer a new non-hormonal option to reduce endometriosis pain for women.
What could go wrong
This is still an early Phase 3 trial, so results may not confirm benefit. Side effects are possible, and the drug may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Women and children's healthcare hospital
Nanning, Jiangsu, China
Contact
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100703, China
Contact
-
Second Affiliated Hospital of Soochow University
Suzhu, Jiangsu, China
-
The International Peace Maternity and Child Health Hospital of the China Welfare Institute
Shanghai, Shanghai Municipality, China
Contact
-
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Contact